183 related articles for article (PubMed ID: 31300829)
21. [Positive and negative symptoms in chronic schizophrenic patients under maintenance therapy with flupenthixol decanoate for a twelve month perioid].
Pach J; Finkbeiner T; Glaser T; Haug J; Osterheider M; Tegeler J
Fortschr Neurol Psychiatr; 1998 Oct; 66(10):442-9. PubMed ID: 9825249
[TBL] [Abstract][Full Text] [Related]
22. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.
Wistedt B
Acta Psychiatr Scand; 1981 Jul; 64(1):65-84. PubMed ID: 7032224
[TBL] [Abstract][Full Text] [Related]
23. The decanoates of flupenthixol and clopenthixol in the treatment of chronic schizophrenic in-patients. Implications for community psychiatry.
Martyns-Yellowe IS
West Afr J Med; 1993; 12(2):110-3. PubMed ID: 8104468
[TBL] [Abstract][Full Text] [Related]
24. Depot bromperidol decanoate for schizophrenia.
Wong D; Adams CE; David A; Quraishi SN
Cochrane Database Syst Rev; 2004; (3):CD001719. PubMed ID: 15266450
[TBL] [Abstract][Full Text] [Related]
25. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Kong DS; Yeo SH
Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
27. Prolactin, flupenthixol decanoate and first episode schizophrenia - clinical and laboratory correlates.
Retief M; Chiliza B; Phahladira L; Emsley R; Asmal L
Metab Brain Dis; 2019 Dec; 34(6):1679-1687. PubMed ID: 31422510
[TBL] [Abstract][Full Text] [Related]
28. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime.
Cookson IB
Int Clin Psychopharmacol; 1987 Apr; 2(2):141-9. PubMed ID: 3298419
[TBL] [Abstract][Full Text] [Related]
29. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O
J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
Correll CU; Kim E; Sliwa JK; Hamm W; Gopal S; Mathews M; Venkatasubramanian R; Saklad SR
CNS Drugs; 2021 Jan; 35(1):39-59. PubMed ID: 33507525
[TBL] [Abstract][Full Text] [Related]
31. Depot perphenazine decanoate and enanthate for schizophrenia.
David A; Quraishi S; Rathbone J
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD001717. PubMed ID: 16034865
[TBL] [Abstract][Full Text] [Related]
32. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
[TBL] [Abstract][Full Text] [Related]
33. Depot fluphenazine decanoate and enanthate for schizophrenia.
David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
Carpenter WT; Buchanan RW; Kirkpatrick B; Lann HD; Breier AF; Summerfelt AT
Am J Psychiatry; 1999 Mar; 156(3):412-8. PubMed ID: 10080557
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of flupentixol decanoate.
Vranckx CH; De Schepper PJ; Hansen T
Acta Psychiatr Belg; 1974 Sep; 74(5):529-32. PubMed ID: 4471034
[No Abstract] [Full Text] [Related]
36. Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting.
Chiliza B; Ojagbemi A; Esan O; Asmal L; Oosthuizen P; Kidd M; Gureje O; Emsley R
Early Interv Psychiatry; 2016 Feb; 10(1):54-62. PubMed ID: 24690088
[TBL] [Abstract][Full Text] [Related]
37. Comparative determination of flupentixol in plasma by gas chromatography and radioimmunoassay in schizophrenic patients.
Balant-Gorgia AE; Balant LP; Genet C; Eisele R
Ther Drug Monit; 1985; 7(2):229-35. PubMed ID: 4024219
[TBL] [Abstract][Full Text] [Related]
38. High dose flupenthixol decanoate in chronic schizophrenia.
McCreadie RG; Flanagan WL; McKnight J; Jorgensen A
Br J Psychiatry; 1979 Aug; 135():175-9. PubMed ID: 387151
[TBL] [Abstract][Full Text] [Related]
39. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S; Crippa A; Siafis S; Patel MX; Orsini N; Davis JM
Am J Psychiatry; 2020 Apr; 177(4):342-353. PubMed ID: 31838873
[TBL] [Abstract][Full Text] [Related]
40. Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia.
Carney MW; Sheffield BF
Br J Psychiatry; 1976 Nov; 129():476-81. PubMed ID: 990663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
